Lilly turns to Amylin
Executive Summary
Lilly will collaborate with Amylin on the development of AC2993 for type 2 diabetes, following Lilly's decision not to pursue Phase III studies of its in-house glucagon-like peptide-1 analogue. Lilly opted not to proceed to Phase III with its drug because of a technical failure in the formulation that caused adverse effects at the injection site, company says. AC2993 has a similar mechanism of action and is in Phase III; the companies hope to file an NDA in 2004. Agreement calls for Lilly to make an $80 mil. upfront payment and purchase $30 mil. in equity. Amylin will receive up to $215 mil. in additional milestone payments, and companies will split U.S. profits equally. Amylin previously worked with Johnson & Johnson on the development of Symlin (pramlintide), but J&J withdrew from the agreement...